Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 10/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | HPGDS | O60760 | 3/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884029 | 0.90 | PRCP (0.38) | PRCPCYP3A4CYP2C9CYP1A2HPGDS | |
| SCHEMBL1884083 | 0.89 | PRCP (0.36) | PRCPCYP3A4CYP2C9CYP1A2HPGDS | |
| SCHEMBL933583 | 0.87 | PRCP (0.39) | PRCPCYP3A4CYP2C9CYP1A2HPGDS | |
| SCHEMBL1884385 | 0.87 | PRCP (0.40) | PRCPCYP3A4CYP2C9CYP1A2HPGDS | |
| SCHEMBL933190 | 0.86 | CHEK2 (0.31) | CHEK2 | |
| SCHEMBL1892016 | 0.85 | CHEK2 (0.32) | CHEK2 | |
| SCHEMBL1887172 | 0.84 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP1A2NR1I2KCNH2 | |
| SCHEMBL933671 | 0.82 | HPGDS (0.39) | PRCPCYP3A4CYP2C9CYP1A2HPGDS | |
| SCHEMBL12661163 | 0.82 | HPGDS (0.39) | PRCPCYP3A4CYP2C9CYP1A2HPGDS | |
| SCHEMBL933373 | 0.82 | CHEK2 (0.30) | CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | PRCP 211/4885CYP3A4 237/4885CYP2C9 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.